SCHEMBL2564407

SCHEMBL2564407

CC1CC1COc1ccc(-n2c(SCCCC(=O)NCCC#N)nc3[nH]ccc3c2=O)cc1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FADS1 O60427 1/20 0.36
JAK1 P23458 4/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
TP53 P04637 4/20 0.35
JAK2 O60674 1/20 0.34
TYK2 P29597 1/20 0.34
JAK3 P52333 1/20 0.34
USP2 O75604 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
MAPT P10636 3/20 0.34
ALDH1A1 P00352 2/20 0.34
TSHR P16473 2/20 0.34
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2566916 0.91 JAK1 (0.40) FADS1JAK1KDM4EPOLBRXFP1
SCHEMBL2569153 0.89 TP53 (0.36) FADS1KDM4EPOLBRXFP1MEN1
SCHEMBL2564523 0.89 JAK1 (0.38) FADS1JAK1KDM4EPOLBRXFP1
SCHEMBL2567307 0.88 RXFP1 (0.39) FADS1KDM4EPOLBRXFP1MEN1
SCHEMBL2564947 0.88 FADS1 (0.36) FADS1JAK1KDM4EPOLBRXFP1
SCHEMBL2561999 0.87 FADS1 (0.42) FADS1JAK1KDM4EPOLBRXFP1
SCHEMBL2569007 0.86 FADS1 (0.37) FADS1JAK1KDM4EPOLBRXFP1
SCHEMBL2560989 0.85 FADS1 (0.39) FADS1JAK1KDM4EPOLBRXFP1
SCHEMBL2565057 0.85 HPGD (0.40) FADS1KDM4EPOLBRXFP1MEN1
SCHEMBL13242291 0.85 FADS1 (0.49) FADS1JAK1KDM4EPOLBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382218-A1 DELTA-5-DESATURASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2011-11-02 EP disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
WO-2010087467-A1 DELTA-5-DESATURASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-05 WO disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed
US-20100190747-A1 Fused ring compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190747-A1 Fused ring compound and use thereof CYP46A1, LTB4R2, PTGES FADS1 140/4885JAK1 242/4885KDM4E 2686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.